Go Deep
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,956 | -11.4 | 1.23 | 0.69 | 1,724.10 |
| Oct 2026 | 19,005 | -11.1 | 1.21 | 0.69 | 1,669.71 |
| Oct 2026 | 19,574 | -10.5 | 1.14 | 0.69 | 1,572.31 |
| Oct 2026 | 19,498 | -10.7 | 1.16 | 0.69 | 1,597.97 |
| Oct 2026 | 19,270 | -11.3 | 1.23 | 0.69 | 1,689.36 |
| Oct 2026 | 19,434 | -10.9 | 1.18 | 0.69 | 1,619.63 |
| Oct 2026 | 19,284 | -11.3 | 1.23 | 0.69 | 1,681.09 |
| Oct 2026 | 18,941 | -12.2 | 1.32 | 0.69 | 1,817.63 |
| Oct 2026 | 19,086 | -11.8 | 1.28 | 0.69 | 1,755.45 |
| Oct 2026 | 19,177 | -11.6 | 1.26 | 0.69 | 1,716.03 |
Sarepta Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 401,251,000.0 | 730,803,000.0 | 442,934,000.0 | 399,356,000.0 |
| Net Profit | -4,890,000.0 | 330,959,000.0 | -282,847,000.0 | -179,947,000.0 |
| EPS | -0.1 | 3.1 | -3.9 | -1.8 |
Sarepta Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 2,198,237,000.0 | 1,901,979,000.0 | 1,243,336,000.0 | 933,013,000.0 | — |
| Net Profit | -713,410,000.0 | 235,239,000.0 | -535,977,000.0 | -703,488,000.0 | — |
| EPS | -7.1 | 2.5 | -5.8 | -8.0 | — |
Sarepta Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 3,349,703,000.0 | 3,963,173,000.0 | 3,264,576,000.0 | 3,128,366,000.0 | — |
| Total Liabilities | 2,209,081,000.0 | 2,435,431,000.0 | 2,405,239,000.0 | 2,743,416,000.0 | — |
| Total Equity | 1,140,622,000.0 | 1,527,742,000.0 | 859,337,000.0 | 384,950,000.0 | — |
Owes vs Owns
Sarepta Therapeutics, Inc. owed $0.52 for every $1 it owned in Jun 2026, down from $0.88 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.52× | 0.66× | 0.61× | 0.74× | 0.88× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Sarepta Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 28.1%Receivables 15.5%Inventory 27.3%Fixed assets (tangible) 14.0%Intangible assets 0.9%Other assets 13.9%
How it's funded — Dec 2025
Long-term debt 24.7%Payables 8.4%Other liabilities 32.5%Shareholders' equity 34.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 939.6 | 1,354.8 | 1,676.2 | 1,989.4 |
| Receivables | 519.6 | 651.7 | 437.0 | 261.6 |
| Inventory | 914.7 | 750.0 | 322.9 | 204.0 |
| Fixed assets (tangible) | 470.6 | 488.6 | 357.1 | 245.0 |
| Intangible assets | 28.9 | 26.9 | 29.6 | 7.6 |
| Long-term investments | 10.6 | 136.9 | 6.5 | 31.3 |
| Other assets | 465.6 | 554.3 | 435.2 | 389.5 |
| Liabilities & equity | ||||
| Short-term debt | 11.4 | 13.5 | 105.5 | 15.5 |
| Long-term debt | 829.0 | 1,137.1 | 1,132.5 | 1,544.3 |
| Payables | 280.8 | 214.4 | 164.9 | 95.9 |
| Other liabilities | 1,087.9 | 1,070.4 | 1,002.3 | 1,087.8 |
| Shareholders' equity | 1,140.6 | 1,527.7 | 859.3 | 384.9 |
| Net tangible assets | 1,111.7 | 1,500.9 | 829.7 | 377.4 |
Sarepta Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -205,479,000.0 | -205,787,000.0 | -500,993,000.0 | -325,346,000.0 | — |
| Investing Activities | 69,641,000.0 | 755,561,000.0 | -165,803,000.0 | -1,046,883,000.0 | — |
| Financing Activities | -168,344,000.0 | 124,806,000.0 | 125,004,000.0 | 232,507,000.0 | — |